sodium oxybate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 49 Diseases   2 Trials   2 Trials   450 News 


«1234»
  • ||||||||||  Wakix (pitolisant) / Ferrer Internacional, Paragon Biosci
    EVALUATION OF ABUSE POTENTIAL OF THE NARCOLEPSY MEDICATION PITOLISANT (116-117) -  Aug 20, 2019 - Abstract #WSS2019WSS_1556;    
    Escalation to the higher (supratherapeutic) dose of pitolisant did not result in increased abuse potential. Together with the lack of any abuse signal in preclinical or clinical studies, these findings suggest that pitolisant has minimal risk of abuse.
  • ||||||||||  Wakix (pitolisant) / Ferrer Internacional, Paragon Biosci, Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health, Sunosi (solriamfetol) / Jazz
    Waking up to narcolepsy: Strategies to improving outcomes (Ballroom A) -  Aug 20, 2019 - Abstract #WSS2019WSS_522;    
    In this symposium, sleep clinicians will be provided with best practices in the diagnosis and treatment of narcolepsy in adults and children. Learning Objectives Describe best practices to achieve earlier and accurate diagnosis of narcolepsy Assess effective treatments for narcolepsy including traditional and emerging therapies Recognize clinical pearls for making a diagnosis of narcolepsy in children and summarize management strategies to improve outcomes Target Audience Physicians and other healthcare professionals involved in the management of sleep disorders
  • ||||||||||  Xywav (calcium/magnesium/potassium/sodium oxybates) / Jazz
    Trial completion:  A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy (clinicaltrials.gov) -  Aug 14, 2019   
    P3,  N=130, Completed, 
    Learning Objectives Describe best practices to achieve earlier and accurate diagnosis of narcolepsy Assess effective treatments for narcolepsy including traditional and emerging therapies Recognize clinical pearls for making a diagnosis of narcolepsy in children and summarize management strategies to improve outcomes Target Audience Physicians and other healthcare professionals involved in the management of sleep disorders Active, not recruiting --> Completed
  • ||||||||||  Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health
    Review, Journal:  Can Slow-Wave Sleep Enhancement Improve Memory? A Review of Current Approaches and Cognitive Outcomes. (Pubmed Central) -  Aug 9, 2019   
    There is some evidence that so-tDCS can also improve certain cognitive outcomes in clinical populations. Overall, future studies should recruit larger sample sizes drawn from more diverse populations, and determine clinical significance and effect sizes of each enhancement methodology.
  • ||||||||||  sodium oxybate / Generic mfg.
    Trial completion date, Trial primary completion date:  Xyrem and Brain Dopamine in Narcolepsy (clinicaltrials.gov) -  Jul 31, 2019   
    P4,  N=30, Recruiting, 
    Overall, future studies should recruit larger sample sizes drawn from more diverse populations, and determine clinical significance and effect sizes of each enhancement methodology. Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: May 2019 --> Mar 2020
  • ||||||||||  Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health
    Journal:  An evaluation of sodium oxybate as a treatment option for narcolepsy. (Pubmed Central) -  Jun 25, 2019   
    It is also an effective therapy for disrupted nocturnal sleep. Sodium oxybate improves narcolepsy symptoms and enhances quality of life in narcolepsy patients.
  • ||||||||||  Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health
    Journal:  Studies of narcolepsy in Russia. Historical view (Pubmed Central) -  Jun 7, 2019   
    The contribution of Russian neurology in the studying of narcolepsy remains underestimated, especially in identifying the clinical features (A. Vein's 'narcoleptic pentad'), the concept of the pathogenesis (hypothalamic syndrome), the determination of provoking factors (postinfectious, postvaccinal reacions) and the use of effective medications (sodium oxybate).
  • ||||||||||  methylphenidate tablet / generics, modafinil / generics
    Review, Journal:  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy. (Pubmed Central) -  May 8, 2019   
    Agents that increase catecholamines and/or LC activity may mitigate EDS and cataplexy by elevating NE regulation of GABAergic inputs from the amygdala. Consequently, novel medications and treatment strategies aimed at preserving and/or modulating Hcrt/orexin-LC circuit integrity are warranted in narcolepsy/cataplexy.
  • ||||||||||  Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health
    Journal:  Treatment of paediatric narcolepsy with sodium oxybate. (Pubmed Central) -  Mar 27, 2019   
    Further studies on chemsex among MSM, which is a rising public health concern, are urgently required. No abstract available
  • ||||||||||  sodium oxybate / Generic mfg.
    Trial completion date, Trial primary completion date:  Xyrem and Brain Dopamine in Narcolepsy (clinicaltrials.gov) -  Jan 30, 2019   
    P4,  N=30, Recruiting, 
    Initiation date: Nov 2018 --> Mar 2019 Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> May 2019
  • ||||||||||  Xywav (calcium/magnesium/potassium/sodium oxybates) / Jazz
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy (clinicaltrials.gov) -  Nov 13, 2018   
    P3,  N=130, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Nov 2018 --> Jun 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
  • ||||||||||  sodium oxybate / Generic mfg.
    Trial completion, Phase classification, Enrollment change:  Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response (clinicaltrials.gov) -  Nov 22, 2017   
    P2,  N=53, Completed, 
    Trial primary completion date: Nov 2017 --> Feb 2017 Recruiting --> Completed | Phase classification: PN/A --> P2 | N=95 --> 53
  • ||||||||||  sodium oxybate / Generic mfg.
    Enrollment change:  Xyrem and Brain Dopamine in Narcolepsy (clinicaltrials.gov) -  Nov 21, 2017   
    P4,  N=30, Recruiting, 
    Recruiting --> Completed | Phase classification: PN/A --> P2 | N=95 --> 53 N=15 --> 30
  • ||||||||||  sodium oxybate / Generic mfg.
    Enrollment open:  Xyrem and Brain Dopamine in Narcolepsy (clinicaltrials.gov) -  Jan 21, 2016   
    P4,  N=15, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Sep 2016 Not yet recruiting --> Recruiting
  • ||||||||||  sodium oxybate / Generic mfg.
    New P4 trial:  Xyrem and Brain Dopamine in Narcolepsy (clinicaltrials.gov) -  Dec 22, 2015   
    P4,  N=15, Not yet recruiting, 
  • ||||||||||  sodium oxybate / Generic mfg.
    Trial completion, Trial primary completion date:  SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) (clinicaltrials.gov) -  Aug 28, 2015   
    P4,  N=10, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Aug 2015
  • ||||||||||  sodium oxybate / Generic mfg.
    Enrollment change:  The Effect of Sodium Oxybate on Sleep Architecture (clinicaltrials.gov) -  Mar 18, 2015   
    P2,  N=0, Withdrawn, 
    Enrolling by invitation --> Active, not recruiting N=10 --> 0